RRM2 and cancer: Phase I and II clinical therapeutic trials have been evaluated using siRNAs to inhibit critical cancer-associated genes, including siRNA-EphA2-DOPC (targeting EphA2), TKM-080301 (targeting PLK1), and CALAA-01 (targeting RRM2).